estriol has been researched along with Delayed Hypersensitivity in 2 studies
hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone
chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Animal models of multiple sclerosis have shown that the pregnancy hormone, estriol, can ameliorate disease and can cause an immune shift." | 9.10 | Treatment of multiple sclerosis with the pregnancy hormone estriol. ( Bouvier, S; Klutch, R; Liva, SM; Odesa, S; Pfeiffer, P; Sicotte, NL; Voskuhl, RR; Wu, TC, 2002) |
| " Animal models of multiple sclerosis have shown that the pregnancy hormone, estriol, can ameliorate disease and can cause an immune shift." | 5.10 | Treatment of multiple sclerosis with the pregnancy hormone estriol. ( Bouvier, S; Klutch, R; Liva, SM; Odesa, S; Pfeiffer, P; Sicotte, NL; Voskuhl, RR; Wu, TC, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sicotte, NL | 1 |
| Liva, SM | 1 |
| Klutch, R | 1 |
| Pfeiffer, P | 1 |
| Bouvier, S | 1 |
| Odesa, S | 1 |
| Wu, TC | 1 |
| Voskuhl, RR | 1 |
| Ezaki, T | 1 |
| Nawa, Y | 1 |
| Hayama, T | 1 |
| Yamaguchi, K | 1 |
| Kotani, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Combination Trial of Copaxone Plus Estriol in RRMS[NCT00451204] | Phase 2 | 158 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A confirmed relapse was defined as new neurological symptoms or worsening of pre-existing symptoms, lasting at least 48 hours in a subject who had been neurologically stable or improving in the previous 30 days, accompanied by objective change in the neurological examination (worsening of 0.5 points on the EDSS or worsening by 1.0 or more points on the pyramidal, cerebellar, brainstem or visual functional system scores), not due to fatigue alone and not associated with fever or infection. (NCT00451204)
Timeframe: 12 months
| Intervention | relapses per year (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 0.25 |
| Placebo Capsules Plus Copaxone Injections | 0.48 |
A confirmed relapse was defined as new neurological symptoms or worsening of pre-existing symptoms, lasting at least 48 hours in a subject who had been neurologically stable or improving in the previous 30 days, accompanied by objective change in the neurological examination (worsening of 0.5 points on the EDSS or worsening by 1.0 or more points on the pyramidal, cerebellar, brainstem or visual functional system scores), not due to fatigue alone and not associated with fever or infection. (NCT00451204)
Timeframe: 24 months
| Intervention | relapses per year (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 0.25 |
| Placebo Capsules Plus Copaxone Injections | 0.37 |
(NCT00451204)
Timeframe: 24 months
| Intervention | probability of relapse at 24 months (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 33.3 |
| Placebo Capsules Plus Copaxone Injections | 42.9 |
Met all criteria for relapse except not confirmed to have increase in EDSS by an independent examiner. (NCT00451204)
Timeframe: 12 months
| Intervention | relapses per year (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 0.33 |
| Placebo Capsules Plus Copaxone Injections | 0.61 |
Met all criteria for relapse except not confirmed to have increase in EDSS by an independent examiner. (NCT00451204)
Timeframe: 24 months
| Intervention | relapses per year (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 0.32 |
| Placebo Capsules Plus Copaxone Injections | 0.46 |
(NCT00451204)
Timeframe: 24 months
| Intervention | probability of relapse event at 24 mo (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 40.5 |
| Placebo Capsules Plus Copaxone Injections | 46.9 |
1 trial available for estriol and Delayed Hypersensitivity
| Article | Year |
|---|---|
Treatment of multiple sclerosis with the pregnancy hormone estriol.
Topics: Adolescent; Adult; Biomarkers; Cross-Over Studies; Estriol; Female; Humans; Hypersensitivity, Delaye | 2002 |
1 other study available for estriol and Delayed Hypersensitivity
| Article | Year |
|---|---|
Modulation of the immune responses against SRBC after oestriol treatment in mice.
Topics: Animals; Antibody Formation; Antibody-Producing Cells; Dose-Response Relationship, Immunologic; Eryt | 1982 |